Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT07392255
PHASE1/PHASE2

An Optimised GA Interventional Trial (Opti-GAIN) to Test if Treatment With CTx001 is Safe and Works for People With Geographic Atrophy (GA)

Sponsor: Complement Therapeutics

View on ClinicalTrials.gov

Summary

This is a clinical study to evaluate the safety, tolerability and efficacy of CTx001, administered via a single subretinal injection, for GA (secondary to AMD). Safety and efficacy will be measured at regular intervals for 2 years after which long-term safety will be assessed annually for up to 5 years.

Official title: A First in Human Phase 1 / 2 Multi-center Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of CTx001 Administered Via a Single Subretinal Injection in Patients With Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (AMD)

Key Details

Gender

All

Age Range

55 Years - Any

Study Type

INTERVENTIONAL

Enrollment

75

Start Date

2025-12-30

Completion Date

2032-06-30

Last Updated

2026-03-17

Healthy Volunteers

No

Interventions

GENETIC

CTx001

Subretinal administration of CTx001

Locations (3)

Midwest Eye Institute

Carmel, Indiana, United States

Sierra Eye Associates

Reno, Nevada, United States

Retina Foundation of the Southwest

Dallas, Texas, United States